Related Experiment Video

Updated: May 9, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma

Martin H Voss1, James J Hsieh, Robert J Motzer

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

Cancer Journal (Sudbury, Mass.)
|July 23, 2013
PubMed

Insights

Novel therapies targeting vascular endothelial growth factor (VEGF) have advanced advanced renal cell carcinoma treatment. New agents aim to overcome resistance and improve outcomes by targeting VEGF signaling more effectively.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The von Hippel-Lindau tumor suppressor and hypoxia-induced factors regulate tumor growth.
  • Vascular Endothelial Growth Factor (VEGF) is a key effector in advanced renal cell carcinoma (RCC).
  • Current VEGF-targeted therapies (VEGF-A, VEGFR2) show success but are limited by incomplete remission and resistance.

Purpose of the Study:

  • To review novel VEGF-directed agents for advanced renal cell carcinoma.
  • To address the limitations of current targeted therapies in RCC.
  • To explore strategies overcoming resistance mechanisms in VEGF-targeted treatment.

Main Methods:

  • Review of current literature on VEGF-targeted therapies in advanced RCC.
  • Analysis of molecular mechanisms of resistance to VEGF inhibition.
  • Identification and categorization of novel therapeutic agents.

Main Results:

  • Existing therapies targeting VEGF-A or VEGFR2 offer benefits but are not curative.
  • Disease progression occurs due to incomplete VEGF suppression or alternative signaling pathways.
  • Novel agents include next-generation multitarget tyrosine kinase inhibitors and biologics.

Conclusions:

  • Next-generation VEGF-directed agents show promise for overcoming resistance in advanced RCC.
  • Further development is needed to achieve complete and durable remissions.
  • Understanding resistance mechanisms is crucial for designing effective treatments.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...